Skip to main content
Which information about ASPAVELI® are you looking for today?

AROUND 50% OF PATIENTS WITH C3G AND PRIMARY IC-MPGN REACH KIDNEY FAILURE WITHIN 10 YEARS OF DIAGNOSIS1

Patients need a treatment that addresses the UNDERLYING DISEASE not just symptom management5-7

Current KDIGO guidelines recommend options that only help manage symptoms2-4

The KHI expert consensus on clinical endpoints in C3G states that efficacy for complement pathway-targeting treatment requires a favourable effect on three endpoints:8

Kidney Health Initiative logo
Aspaveli - triad graphic

We need a treatment that achieves CONVINCING EFFICACY on all THREE ENDPOINTS from the KHI expert consensus8,9

RaDaR, GLOSEN and Ghadder et al10-12 identifed >50% proteinuria reduction as a key marker for reducing the risk of progression to kidney failure.

1 pixel spacer
Aspaveli product logo with new endline

EMA indication:

ASPAVELI® is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.13

For the full EMA Aspaveli SmPC, please click here

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via their national pharmacovigilance reporting system. Suspected adverse reactions should also be reported to Sobi via email at [email protected].

Abbreviations

C3, complement 3; C3G, C3 glomerulopathy;  eGFR, estimated glomerular filtration rate; IC-MPGN, immune complex-mediated membranoproliferative glomerulonephritis; KHI, Kidney Health Initiative; RAS, renin-angiotensin system.

References

  1. Halfon M, et al. Kidney Int Rep. 2024;10(1):75–86.

  2. Heidenreich K, et al. Front Nephrol 2024;4:1460146. 

  3. Trimarchi H. World J Nephrol. 2017;6(5):221–228. 

  4. Kavanagh D, et al. Kidney Int Rep 2026;11:17–31. 

  5. Bomback AS, et al. Kidney Int Rep 2024;10(1):17–28.  

  6. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int 2021;100(4S):S1–276.  

  7. Heiderscheit AK, et al. Am J Med Genet C Semin Med Genet 2022;190:344–57.

  8. Nester CM, et al. Clin J Am Soc Nephrol 2024;19:1201–8. 

  9. Wong E, et al. Kidney Int Rep 2023;8(12):2754–64. 

  10. Masoud S, et al. Kidney Int 2025;108(3):455–69. 

  11. Caravaca-Fontán F, et al. Nephrol Dial Transplant 2022;37:1270–80. 

  12. Ghaddar M, et al. Clin J Am Soc Nephrol 2025;20(8):1119–31.

  13. Aspaveli EMA Summary of product characteristics. Swedish Orphan Biovitrum AB (publ) January 2026.

This website contains information based on the ASPAVELI® Summary of Product Characteristics as approved by European Commission. License conditions vary between countries. Please consult your local Summary of Product Characteristics or Prescribing Information.
 

PP-32963